Trisha Shetty (Editor)

Weifa

Updated on
Edit
Like
Comment
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit
Type
  
Allmennaksjeselskap

Industry
  
Pharmaceutical

Website
  
www.weifa.no

Founded
  
1940

Traded as
  
OSE: WEIFA

Revenue
  
500mill NOK (2012)

Number of employees
  
99

Headquarters
  
Oslo, Norway, Norway

Weifa wwwncggroupcomwpcontentuploads201312weifapng

Stock price
  
P7C (FRA) € 2.87 0.00 (-0.03%)7 Apr, 8:07 AM GMT+2 - Disclaimer

Subsidiaries
  
Cederroth, Weifa AS, Aqualis Offshore UK Ltd., Tristein AS

Weifa is a Norwegian pharmaceutical company headquartered in Oslo with production facilities in Kragerø.

Contents

Weifa is one of the world’s largest producers of Metformin hydrochloride and a leading producer of alkaloid opiates. Production facilities follow GMP standards.

History

Weifa was founded by pharmacist Olaf Weider in 1940.

Therapeutic areas

Weifa focuses on three therapeutic areas:

  1. Pain management
  2. Diabetes management
  3. Food supplements

Products

  • bra!: Evening primrose oil.
  • Bronkyl: Expectorant effervescent tablet.
  • Dexyl: Nasal spray.
  • Fanalgin: Pain reliever and fever reducer with an addition of caffeine.
  • Ferromax: Iron supplement.
  • Fluormax: Fluorine supplements.
  • Ibux: A brand name for ibuprofen.
  • Ibux Gel: A gel version of Ibux.
  • Nazamér: Salt water spray.
  • Nazaren: Nasal spray.Salt water spray.
  • Paracet: A brand name for paracetamol.
  • Paracetduo: Similar to Paracet with the addition of caffeine for increased pain relief.
  • Proxan: Brand name for naproxen.
  • Pyrivir: Relieves symptoms of cold sores.
  • Samin: Symptom relief in patients with Osteoarthritis.
  • Tigerbalsam: Heat rub.
  • Tussin: Cough medicine.
  • Weifa-C Nypeekstrakt: Vitamin C from rose hip extract.
  • Weifa C-vitamin brusetabletter: Vitamin C effervescent tablets.
  • Weifa Kalsium: Calcium supplements.

    • Active ingredients

  • Codeine: Used in pain relievers and cough medicine.
  • Metformin: Used in first-line treatment of diabetes mellitus type 2.
  • Pholcodine: Used in cough medicine.

    • Development

    With a total of over 99 employees, Weifa is today generating an annual turnover of approximately €40 million (35% of the turnover is achieved internationally). Weifa bases its development on 3 criteria:

    1. International expansion
    2. Expertise in pharmaceuticals and fine chemicals
    3. Partnership agreements

    Norway

    Weifa has market leadership in pain management products for the Norwegian market, with a portfolio of branded products that includes established brand names such as the Ibux tablets, Paracet tablets and Paralgin Forte tablets. Branded products accounts for approximately 70% of net sales.

    Export

    Weifa’s leading export markets are Germany and United Kingdom. Besides these two essential export markets, Weifa has a long-standing presence in all the main countries of the European Union, in Eastern Europe, in Africa, in North America, in South America and in Asia.

    References

    Weifa Wikipedia
    (Text) CC BY-SA